{
    "clinical_study": {
        "@rank": "94179", 
        "arm_group": [
            {
                "arm_group_label": "Ticagrelor", 
                "description": "A Group which treated with Ticagrelor"
            }, 
            {
                "arm_group_label": "Clopidogrel", 
                "description": "A Group which treated with Clopidogrel"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to evaluate the efficacy and safety of clopidogrel in\n      stabilized patients with acute myocardial infarction (AMI) who performed percutaneous\n      coronary intervention (PCI) with drug-eluting stents (DES) compared with ticagrelor.\n\n      In this study, 3,288 patients with AMI who underwent PCI with DES and took dual antiplatelet\n      therapy as aspirin and ticagrelor during 1 month from index PCI will be randomized to\n      aspirin and ticagrelor versus aspirin and clopidogrel during 11 months."
        }, 
        "brief_title": "Compare Efficacy and Safety of Clopidogrel vs Ticagrelor in Stabilized Patients With Acute Myocardial Infarction After Percutaneous Coronary Intervention; TicAgrelor Versus CLOpidogrel in Stabilized Patients With Acute Myocardial Infarction: TALOS-AMI", 
        "completion_date": {
            "#text": "December 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Acute Myocardial Infarction", 
        "condition_browse": {
            "mesh_term": [
                "Infarction", 
                "Myocardial Infarction"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Women and men, aged \u2265 18 y\n\n          2. Patients with acute myocardial infarction (non-ST-elevation myocardial infarction or\n             ST-elevation myocardial infarction) who take a medicine with ticagrelor for 30 days\n             after undergo percutaneous coronary intervention with drug-eluting stent\n\n          3. Patients who have previously given their informed consent for participation in the\n             study\n\n          4. Female patients, with childbearing potential who have committed to using adequate\n             contraception\n\n        Exclusion Criteria:\n\n          1. Cardiogenic shock\n\n          2. Acitve internal bleeding, history of bleeding diathesis, or coagulopathy\n\n          3. Gastrointestinal bleeding, genitourinary bleeding, hemoptysis, or vitreoretinal\n             bleeding\n\n          4. Major surgery within 6 weeks prior to screening\n\n          5. Intracranial bleeding or structural abnormalities\n\n          6. Anemia (hemoglobin < 10 g/dL) at the time of screening or Platelet count of less than\n             100,000/mm3 at the time of screening\n\n          7. Oral anticoagulation that cannot be safely discontinued for the duration of the study\n\n          8. Daily treatment with nonsteroidal anti-inflammatory drugs or clooxygenase-2\n             inhibitors\n\n          9. Malignancy or life expectancy < 1 y\n\n         10. Known severe hepatic dysfunction\n\n         11. Symptomatic patients with sinus bradycardia or atrioventricular block\n\n         12. Symptomatic patients with chronic obstructive pulmonary disease\n\n         13. Intolerance of or allergy to aspirin, ticagrelor, or clopidogrel\n\n         14. Treatment within the 3 months with an investigational drug or are presently enrolled\n             in another drug or device study (except registry and observational study)\n\n         15. Women who are known to be pregnant, have given birth within the past 90 d, or are\n             breast-feeding\n\n         16. Patients who performed kidney transplantation or required dialysis\n\n         17. A patient who has genetic disorder; for example galactose intolerance, Lapp lactase\n             deficiency or glucose galactose malabsorption.\n\n         18. Any other condition that may put the patient at risk or influence study results in\n             the investigators' opinion"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years", 
            "sampling_method": "Probability Sample", 
            "study_pop": {
                "textblock": "In this study, 3,288 patients with AMI who underwent PCI with DES and took dual\n        antiplatelet therapy as aspirin and ticagrelor during 1 month from index PCI will be\n        randomized to aspirin and ticagrelor versus aspirin and clopidogrel during 11 months."
            }
        }, 
        "enrollment": {
            "#text": "3288", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 17, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02018055", 
            "org_study_id": "TALOS-AMI"
        }, 
        "intervention": [
            {
                "arm_group_label": "Ticagrelor", 
                "intervention_name": "Ticagrelor", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Clopidogrel", 
                "intervention_name": "Clopidogrel", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Clopidogrel", 
                "Ticlopidine", 
                "Ticagrelor"
            ]
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "December 17, 2013", 
        "location": {
            "contact": {
                "email": "kbseung@catholic.ac.kr", 
                "last_name": "KI-BAE SEUNG, M.D., Ph.D", 
                "phone": "822-2258-1142"
            }, 
            "facility": {
                "address": {
                    "city": "Seoul", 
                    "country": "Korea, Republic of", 
                    "zip": "137701"
                }, 
                "name": "Seoul St.Mary's Hospital"
            }, 
            "investigator": {
                "last_name": "KI-BAE SEUNG, M.D., Ph.D", 
                "role": "Principal Investigator"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_groups": "2", 
        "official_title": "A Prospective, Multicenter, Randomized, Open-label Trial to Compare Efficacy and Safety of Clopidogrel vs Ticagrelor in Stabilized Patients With Acute Myocardial Infarction After Percutaneous Coronary Intervention; TicAgrelor Versus CLOpidogrel in Stabilized Patients With Acute Myocardial Infarction: TALOS-AMI", 
        "overall_contact": {
            "email": "kbseung@catholic.ac.kr", 
            "last_name": "Ki-Bae Seung, Ph.D.", 
            "phone": "822-2258-1142"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "South Korea: Ministry of Food and Drug Safety", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Composite endpoint of cardiac death, myocardial infarction, stroke, and bleeding (BARC bleeding type 2, 3, or 5) at one year after index percutaneous coronary intervention", 
            "measure": "Cumulative incidence rate of MACCE(CV death, MI, stroke) plus BARC bleeding(type 2,3,or 5) at 1 year from baseline.", 
            "safety_issue": "No", 
            "time_frame": "1 month to 12months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02018055"
        }, 
        "responsible_party": {
            "investigator_affiliation": "The Catholic University of Korea", 
            "investigator_full_name": "Ki-Bae Seung", 
            "investigator_title": "Professor", 
            "responsible_party_type": "Sponsor-Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "Cumulative incidence rate of MACCE(CV death, MI, stroke) at each visit.", 
                "measure": "Cumulative incidence rate of MACCE(CV death, MI, stroke) at each visit.", 
                "safety_issue": "No", 
                "time_frame": "1 month to 3months, 6months, 12months"
            }, 
            {
                "description": "Cumulative incidence rate of Bleedings according to the BARC definitions (type 2, 3 or 5)  at each visit.", 
                "measure": "Cumulative incidence rate of Bleedings according to the BARC definitions (type 2, 3 or 5)  at each visit.", 
                "safety_issue": "No", 
                "time_frame": "1 month to 3months, 6months, 12months"
            }, 
            {
                "description": "Cumulative incidence rate of Ischemia Driven Revascularization including PCI or CABG at each visit.", 
                "measure": "Cumulative incidence rate of Ischemia Driven Revascularization including PCI or CABG at each visit.", 
                "safety_issue": "No", 
                "time_frame": "1 month to 3months, 6months, 12months"
            }, 
            {
                "description": "Cumulative incidence rate of Cardiac death at each visit.", 
                "measure": "Cumulative incidence rate of Cardiac death at each visit.", 
                "safety_issue": "No", 
                "time_frame": "1 month to 3months, 6months, 12months"
            }, 
            {
                "description": "Cumulative incidence rate of Death from any cause at each visit.", 
                "measure": "Cumulative incidence rate of Death from any cause at each visit.", 
                "safety_issue": "No", 
                "time_frame": "1 month to 3months, 6months, 12months"
            }, 
            {
                "description": "Cumulative incidence rate of Death from vascular cause at each visit.", 
                "measure": "Cumulative incidence rate of Death from vascular cause at each visit.", 
                "safety_issue": "No", 
                "time_frame": "1 month to 3months, 6months, 12months"
            }, 
            {
                "description": "Cumulative incidence rate of Acute MI at each visit.", 
                "measure": "Cumulative incidence rate of Acute MI at each visit.", 
                "safety_issue": "No", 
                "time_frame": "1 month to 3months, 6months, 12months"
            }, 
            {
                "description": "Cumulative incidence rate of Stroke at each visit.", 
                "measure": "Cumulative incidence rate of Stroke at each visit.", 
                "safety_issue": "No", 
                "time_frame": "1 month to 3months, 6months, 12months"
            }, 
            {
                "description": "Cumulative incidence rate of Stent thrombosis(definite or probable) at each visit.", 
                "measure": "Cumulative incidence rate of Stent thrombosis at each visit.", 
                "safety_issue": "No", 
                "time_frame": "1 month to 3months, 6months, 12months"
            }
        ], 
        "source": "The Catholic University of Korea", 
        "sponsors": {
            "collaborator": {
                "agency": "Chonnam National University Hospital", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "Ki-Bae Seung", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 2014", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "December 2013"
    }
}